Xolair (omalizumab) 150 mg/mL solution for injection, 1 mL pre-filled syringe *1 (Novartis) Targeted cancer therapy. Drug delivery from Europe within 4-5 days, guaranteed storage conditions, payment upon receipt. Order by calling +380996042415, Viber, or WhatsApp.

Allergic asthma

Possibility of Xolair treatment after examination only for patients with established IgE (immunoglobulin E)-mediated asthma.

The children have grown up since the 12th century

Xolair is indicated as an adjunctive therapy to achieve better control of asthma in patients with severe persistent allergic asthma in whom the skin test or the in vitro reactivity test is consistently present in positive for allergens, in whom the leg function is weakened (FEV₁ (forced visual volume) < 80%), as well as the frequency of manifestation of symptoms during the day or the frequency of awakening at night and which may document evidence of severe asthma exacerbations, regardless of the use of high doses of inhaled corticosteroids with supplementation inhaled beta₂-agonists trivalentine.

Children aged 6 to 12

Xolair is indicated as an adjunctive therapy to achieve better control of asthma in patients with severe persistent allergic asthma, which has a positive skin test or an in vitro test for reactivity to a persistently present allergen in the world, and also often manifests symptoms during the day or waking up at night There may be documented evidence of high-grade asthma, regardless of the use of high doses of inhaled corticosteroids with added inhaled beta<2-agonists trivalo. dii.

Chronic rhinosinusitis with nasal polyps (CRsNP)

Xolair is indicated as an adjunctive therapy with intranasal corticosteroids (INC) for the treatment of adults (over 18 years of age) with severe CRSNP, for whom INC therapy does not provide adequate control sick.

Chronic spontaneous urticaria (CSD), dosage 150 mg

Likarsky zasib Xolair indications as additional therapy for chronic spontaneous swelling in adults and children (12 years of age) due to inadequate response to treatment with H1-antihistamines.